This phase 2 trial showed that a single subcutaneous dose of L9LS at the highest dose tested (300 mg) provided protective efficacy of 69.9% against P. falciparum infection and 77.4% against ...

Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered ...

A 47-year-old man presented with 2-day history of weakness and fever. Laboratory studies showed pancytopenia. A bone marrow biopsy showed promyelocytes with abundant intracellular rods.

CAR T-Cells and Safety Signals — ITT Episode 29: This podcast episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of ...

The case description for a Case Records of the Massachusetts General Hospital appears below. A 30-year-old woman was evaluated because of back pain, leg stiffness, and falling. Tone was increased ...